Johnson & Johnson Global Head of R&D: Might have an emergency authorization by 'the end of February'
04:28
Share this -
copied
Dr. Mathai Mammen, the Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson joins Andrea Mitchell Reports to explain that their vaccine is 100% effective in preventing hospitalizations and deaths. "It’s protective 100% against those that need to go to the hospital," he says. He also gives a timeline for getting the vaccine approved and distributed, saying they might have an emergency use authorization by the end of February, and 100 million doses by June.Jan. 29, 2021
UP NEXT
Matt Pottinger: ‘Xi Jinping sees himself as an agent of chaos’ which ‘works to Beijing’s advantage’
05:47
Goodwin: ‘I wish young people could look back’ & ‘take some hope from’ 1960s protests
07:08
Supreme Court hears challenge to Idaho's near-total abortion ban
04:52
Stephen Breyer: ‘rule of law’ is a weapon against chaos
10:30
Fmr. U.S. Supreme Court Justice on presidential immunity
03:52
'Rather diminishing': Marc Short on Trump's lack of control in courtroom